Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Revenues Increase for Q3, Boosted 4.6 Percent by Currency Exchange

NEW YORK, Oct. 21 (GenomeWeb News) - Sigma-Aldrich today reported net sales of $341 million for the quarter ended Sept. 30, up from $314 million for the same period last year.

 

The increase reflected a 4.6-percent benefit from currency exchange rates, the company said. Around half of  Sigma's sales are in currencies other than dollars, and its revenues reflect benefits from exchange rates.

 

Sigma's biotechnology business unit, which sells its product lines of molecular biology tools, reported sales of $75 million, up from $72 million for the year-ago quarter.

 

The St. Louis-based company had a gross profit of $182 million for the period, compared to $164 million for the year-ago quarter.

 

The firm had R&D expenses of $10.5 million for the quarter, compared to $10.2 million for the year-ago period.

 

Sigma finished the quarter with $134 million in cash and cash equivalents on hand, compared to $128 million for the year-ago quarter.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.